Melanotan 2 vs melanotan 1

Melanotan 1 (MT1, also known as afamelanotide) and melanotan 2 (MT2) are both synthetic analogs of alpha-MSH developed at the University of Arizona. They share the same fundamental mechanism — melanocortin receptor activation to stimulate melanin production — but differ significantly in receptor selectivity, side effect profile, duration of action, and regulatory status. This page provides a direct comparison to help understand when each compound is more appropriate.

Melanotan 1 vs melanotan 2: the fundamental difference

The key difference between melanotan 1 and melanotan 2 is receptor selectivity. Melanotan 1 (afamelanotide) is a linear peptide that preferentially activates MC1R — the melanocortin receptor directly responsible for melanin production in skin — with minimal activity at MC3R, MC4R, and MC5R. Melanotan 2 is a cyclic peptide that activates MC1R, MC3R, MC4R, and MC5R with relatively equal affinity. This non-selectivity is why MT2 produces tanning alongside sexual function effects (MC3R/MC4R), appetite suppression (MC4R), and other systemic effects that MT1 largely avoids.

Melanotan 2 vs melanotan 1: comparison table

Melanotan 1: FDA-approved as Scenesse for EPP

Melanotan 1 achieved what melanotan 2 never did — FDA approval. Under the brand name Scenesse (afamelanotide, manufactured by Clinuvel Pharmaceuticals), MT1 was approved by the FDA in 2019 for the treatment of erythropoietic protoporphyria (EPP), a rare genetic condition in which patients experience extreme photosensitivity and cannot tolerate sun exposure. Scenesse is administered as a subcutaneous implant that slowly releases afamelanotide over approximately 60 days, producing sustained melanin production that provides photoprotection for EPP patients.

Scenesse's approval was based on MT1's favorable safety profile — its MC1R selectivity means it produces tanning without the sexual, appetite, and gastrointestinal side effects that prevented MT2 from advancing through clinical development. However, Scenesse is only approved for EPP and costs approximately $100,000+ per year, making it inaccessible for cosmetic tanning use.

Melanotan 2 vs melanotan 1: which is better for tanning?

For pure tanning effect, melanotan 2 produces faster and more intense results than melanotan 1. MT2's activation of multiple melanocortin receptors creates a broader melanogenesis signal, and its cyclic structure provides greater receptor binding affinity than MT1's linear structure. Most users see visible tanning from MT2 within 1–2 weeks, while MT1 typically requires 3–4 weeks for comparable results.

However, MT1 produces tanning with significantly fewer side effects. Users who cannot tolerate MT2's nausea, flushing, or sexual function effects may find MT1 more manageable despite the slower onset. The tradeoff is clear: MT2 is faster and more potent but comes with more side effects; MT1 is slower and milder but better tolerated.

Melanotan 2 vs melanotan 1: safety comparison

Melanotan 1's MC1R selectivity gives it a meaningfully better safety profile than MT2. By avoiding significant MC3R/MC4R activation, MT1 eliminates the sexual function side effects, reduces nausea and appetite suppression, and limits the compound's systemic effects to primarily the skin. This selectivity is what enabled MT1 (as Scenesse) to achieve FDA approval — the benefit-risk ratio was favorable enough for regulatory acceptance.

Both compounds share the melanocyte-related safety concerns — mole darkening, new mole formation, and the theoretical melanoma risk — because both activate MC1R on melanocytes. These risks are inherent to any compound that stimulates melanin production and are not eliminated by selectivity improvements. Both MT1 and MT2 users should monitor moles and have regular dermatological screening.

Melanotan 2 vs melanotan 1: PT-141 (bremelanotide)

The sexual function effects of melanotan 2 were potent enough that a derivative — PT-141 (bremelanotide) — was developed specifically as a sexual dysfunction treatment. PT-141 was FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. This represents an interesting divergence from the original melanotan research: MT1's selectivity led to a tanning drug (Scenesse), while MT2's non-selectivity led to a sexual function drug (Vyleesi). The parent compound MT2 remains unapproved, sitting between its two FDA-approved offspring.